Chun Kiat Lee

Mr. Chun Kiat Lee

National University Health System, Singapore, Central Singapore, Singapore
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
KOKean Hean Ooi
Kean Hean Ooi
MLMengying Mandy Liu
Mengying Mandy Liu
JTJie Wen Douglas Tay
Jie Wen Douglas Tay
STSeok Yee Teo
Seok Yee Teo
PKPornchai Kaewsapsak
Pornchai Kaewsapsak
MTMeng How Tan
Meng How Tan
Extensive testing is essential to break the transmission of SARS-CoV-2, which causes the ongoing COVID-19 pandemic. Here, we present a CRISPR-based diagnostic assay that is robust to viral genome mutations and temperature, produces results fast, can be applied directly on nasopharyngeal (NP) specimens without RNA purification, and incorporates a human internal control within the same reaction. Specifically, we show that the use of an engineered AsCas12a enzyme enables detection of wildtype and mutated SARS-CoV-2 and allows us to perform the detection step with loop-mediated isothermal amplification (LAMP) at 60-65 °C. We also find that the use of hybrid DNA-RNA guides increases the rate of reaction, enabling our test to be completed within 30 minutes. Utilizing clinical samples from 72 patients with COVID-19 infection and 57 healthy individuals, we demonstrate that our test exhibits a specificity and positive predictive value of 100% with a sensitivity of 50 and 1000 copies per reaction (or 2 and 40 copies per microliter) for purified RNA samples and unpurified NP specimens respectively.

18 July 2012 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
MBMichelle N.D. Balm
Michelle N.D. Balm
CLChun Kiat Lee
Chun Kiat Lee
HLHong Kai Lee
Hong Kai Lee
LCLily Chiu
Lily Chiu
EKEvelyn S.C. Koay
Evelyn S.C. Koay
JTJulian Tang
Julian Tang

17 June 2021 in Indoor Air
Verified
Journal Article
Closed access
PDF file
JPJin Pan
Jin Pan
JTJulian Tang
Julian Tang
MCMiguela Caniza
Miguela Caniza
Jean-Michel HeraudJean-Michel Heraud
Jean-Michel Heraud
EKEvelyn Koay
Evelyn Koay
LMLinsey Marr
Linsey Marr

1 September 2010 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
HLHong Kai Lee
Hong Kai Lee
CLChun Kiat Lee
Chun Kiat Lee
TLTze Ping Loh
Tze Ping Loh
JTJulian Tang
Julian Tang
LCLily Chiu
Lily Chiu
EKEvelyn Siew-Chuan Koay
Evelyn Siew-Chuan Koay

15 August 2012 in Journal of Medical Virology
Verified
Journal Article
Open access
HLHong Kai Lee
Hong Kai Lee
TLTze Ping Loh
Tze Ping Loh
CLChun Kiat Lee
Chun Kiat Lee
JTJulian Tang
Julian Tang
LCLily Chiu
Lily Chiu
EKEvelyn Siew‐Chuan Koay
Evelyn Siew‐Chuan Koay
A high throughput universal influenza A and B duplex real‐time RT‐PCR was developed to meet effectively the heightened surveillance and diagnostic needs essential in managing influenza infections and outbreaks. Primers and probes, designed to target highly conserved regions of the matrix protein of influenza A and the nucleoprotein of influenza B, were optimized using the high‐throughput LightCycler 480 II system. Analytical sensitivity and specificity were characterized using RNA transcripts diluted serially, archived non‐influenza respiratory viruses, and proficiency test samples. Eighty‐nine clinical samples were tested in parallel against existing influenza A and B monoplex assays. Once validated, the duplex assay was applied prospectively on 2,458 clinical specimens that were later subtyped. In April 2011, the emergence of an influenza B variant necessitated the inclusion of an additional modified probe for influenza B and revalidation of the revised protocol. The lower detection limits of the assay were 50 copies/PCR. There was no cross‐reactivity against any non‐influenza respiratory virus and all proficiency testing materials were identified correctly. The parallel testing revealed a 98.9% overall agreement. Routine application of the assay revealed high sensitivity and specificity for the detection of influenza A/H1N1/2009, A/H3N2 and influenza B. Assay Cq values correlated well between the pre‐ and post‐revision protocols for influenza A (r2 = 0.998) and B (r2 = 0.999). The revised protocol detected three additional novel influenza B variant cases in 200 specimens reported previously as influenza B negative. This in‐house assay offers a highly sensitive and specific option for laboratories seeking to expand their influenza testing capacity. J. Med. Virol. 84:1646–1651, 2012.

1 November 2014 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
PHPatrick Harris
Patrick Harris
DWDingyuan Alvin Wang
Dingyuan Alvin Wang
MYMo Yin
Mo Yin
CLChun Kiat Lee
Chun Kiat Lee
SASophia Archuleta
Sophia Archuleta